In this month’s issue of PME magazine we balance the changes that are already the theme of 2017 with some much needed stability in the form of a look at family-owned or foundation-run pharmaceutical companies.
Such European businesses include Germany’s Boehringer Ingelheim, Italy’s Chiesi and Denmark’s LEO Pharma, whose president and CEO Gitte Aabo talked to us about playing the long game and how this sees it through times of boom and bust. Read the rest of this entry »
At almost 310 metres high The Shard is the tallest building in the capital, towering over its London neighbours in Southwark.
One of those in its shadow is the site for what will become Science Gallery London, an exhibition and performance space that, from 2018, hopes to connect scientific researchers, students, local communities and artists. Read the rest of this entry »
As PME‘s first issue of the year comes out the European pharmaceutical industry goes into 2017 steeling itself for the start of Brexit, with plenty of words already devoted to what we don’t know about the implications of the UK’s vote to leave the European Union.
This year should see the phony war end and hostilities begin in earnest when the UK formally triggers Article 50 and commences the official process of withdrawing from the EU. Read the rest of this entry »
The European Commission is not necessarily best known for its lightning reactions, but you do know that when it gets its teeth into something it’s not likely to let go.
So it may again prove to be with a technology that already seemed to be everywhere in 2016 and this year shows every sign of continuing that trend. Read the rest of this entry »
In screenwriting the three-act structure progresses from setup to confrontation to resolution, with the first act used for establishing the main characters.
It’s a device for fiction of course, but much of this year feels like just that. In fact, looking back on the last 12 months, 2016 also feels like a setup for events yet to come. Read the rest of this entry »